Brief: ADC Therapeutics Doses First Patient In Phase 1B Clinical Trial Of Zynlonta In Combination With Other Anti-Cancer Agents
29/06/2022 12:44
June 29 (Reuters) - ADC Therapeutics SA ADCT.N :
* ADC THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1B CLINICAL
TRIAL
OF ZYNLONTA® (LONCASTUXIMAB TESIRINE-LPYL) IN COMBINATION WITH
OTHER ANTI-CANCER AGENTS
Source text for Eikon: ID:nBw62pskza
Further company coverage: ADCT.N
Recent news on Adc Therapeutics
See all newsBrief: Adc Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics SA reports results for the quarter ended June 30 - Earnings Summary
ADC Therapeutics Q2 loss narrows; cuts 17% workforce
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview